Clinical trial · Observational
Preconditioning Chemotherapy Combination With Cytokine Induced Killer Cell (CIK) Immunotherapy
Preconditioning Chemotherapy Combined With Cytokine Induced Killer Cell Immunotherapy in Advanced Non Small Cell Lung Cancer
NCT01902875CI-TRIAL-00011402unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This clinical Trial is proposed to explore whether preconditioning chemotherapy of Paclitaxel+cisplatin(TP)regimen combined with autologous adoptive CIK cell immunotherapy could benefit NSCLC patients with a better clinical outcome.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non Small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| CIK cell therapy | Biological | — | UNRESOLVED |
| Paclitaxel + Cisplatin | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- TP regimen + CIK group
- description
- This group are treated with Preconditioning Chemotherapy （Paclitaxel + Cisplatin） Combined with Cytokine Induced Killer Cell Immunotherapy （CIK cell therapy）.
- interventionNames
- Drug: Paclitaxel + Cisplatin
- Biological: CIK cell therapy
- label
- TP regimen group
- description
- This group are treated with Chemotherapy （Paclitaxel + Cisplatin） only.
- interventionNames
- Drug: Paclitaxel + Cisplatin
Primary outcomes (1)
- measure
- Disease Control Rate(DCR) and Disease Progression-Free Survival(PFS)
- timeFrame
- 8 weeks
- description
- Use CT and MRI for scalable lesion to evaluate the efficacy of preconditioning chemotherapy of TP regimen (PTX+DDP) combined with autologous adoptive CIK cell immunotherapy in NSCLC.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 40 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: 1. Primary non small cell lung cancer patients with pathology diagnosis with clinical TNM Classification of Malignant Tumours (TNM) stage (IIIa\~IV) can not accept operation or unwilling to operation; 2. 40\~70 year old, Eastern Cooperative Oncology Group (ECOG) score ≤ 2 points, estimate survival \> 3 months; 3. Blood White Blood Cell(WBC)≥ 4×109/L, Hb ≥ 100g/L, Platelet Count(PLT)≥ 80×109/L; Alanine aminotransferase(ALT) and aspartate aminotransferase(AST)≤ 2 times of normal upper value; Serum Cr ≤ 2 normal upper value; 4. With more than one scalable lesions; 5. Without any other malignant disease; 6. Patients Voluntary attempt, and informed consent. Exclusion Criteria: 1. Hypersusceptible to paclitaxel, cisplatin, CIK cells and IL-2; 2. With no scalable lesions; 3. Pregnant or lactating women; 4. Uncontrolled brain metastasis with symptoms or with psychal problems can not describe subjective symptoms; 5. With serious visceral organs failure; 6. Patients with the conditions affect the administration, absorb, distribution, metabolism and excretion of the drugs; 7. History of cardiovascular disease, including congestive heart failure, unstable angina patients, myocardial infarction; Cachexia; or other deadly diseases; 8. Serious uncontrollable infection; 9. At present Is receiving other cancer treatment (such as chemotherapy, radiation therapy, chemotherapy, immunosuppressants and thrombosis, targeted agents); Now or recently will join another experimental clinical study; 10. Other situations that the researchers considered unsuitable for this study (such as mental illness, drug abuse, etc.).
References
Publications (0)
Data not yet available
No reference posted for this study.